Table 3 Patient characteristics and relationship to clinical impact†

Immunocompromised

45 (56)

24 (53.3)

21 (46.7)

0.522

Organ transplant

21 (26)

6 (28.6)

15 (71.4)

0.003

1.67–14.95

Stem cell transplant

3 (4)

3 (100)

0

Solid tumor

2 (2)

2 (100)

0

Hematologic malignancy

22 (27)

15 (68.2)

7 (31.8)

0.189

HIV/AIDS

1 (1)

1 (100)

0

Autoimmune disease

3 (4)

1 (33.3)

2 (66.7)

Hardware or prosthesis

14 (18)

7 (50)

7 (50)

0.593

Vascular graft

6 (7)

4 (66.7)

2 (33.3)

0.691

Prosthetic joint or orthopedic hardware

1 (1)

0

1 (100)

Mechanical cardiac device

1 (1)

0

1 (100)

Prosthetic valve

8 (10)

3 (37.5)

5 (62.5)

0.285

Diabetes

13 (16)

6 (50)

6 (50)

0.626

Infectious syndrome/clinical diagnosis

 Sepsis/Septic shock

14 (15)

4 (28.6)

10 (71.4)

0.02

1.176–14.765

 Bacteremia

3 (3)

1 (33.3)

2 (66.7)

 Vascular graft infection

7 (7)

4 (57.1)

3 (42.9)

1

 Endocarditis

13 (13)

6 (46.2)

7 (53.8)

0.414

 Respiratory failure/pneumonia

30 (31)

14 (48.3)

15 (51.7)

0.265

 Bone/Joint infection

4 (4)

3 (75)

1 (25)

 CNS infection (meningoencephalitis)

10 (10)

7 (77.8)

2 (22.2)

0.285

 Fever unknown origin

10 (10)

5 (50)

5 (50)

0.74

 Unexplained leukocytosis

2 (2)

1 (50)

1 (50)

 Sinusitis

1 (1)

1 (100)

0

 Skin and soft tissue infection

1 (1)

0

1 (100)

 Others

1 (1)

1 (100)

0

Antimicrobial agents administered prior to mcfDNA test

72 (90)

39 (55.7)

31 (44.3)

1

 Less than 7 days

35 (49)

13 (38.2)

21 (61.8)

0.004

1.537–11.476

 More than 7 days

37 (51)

26 (72.2)

10 (27.8)

0.004

 No antimicrobial agents prior to mcfDNA test

8 (10)

5 (62.5)

3 (37.5)

1

Final diagnosis

 Bacterial

26 (31)

15 (60)

10 (40)

0.661

 Fungal

21 (25)

12 (57.1)

9 (42.9)

0.937

 Viral

10 (12)

6 (60)

4 (40)

1

 Non-infectious

28 (33)

14 (51.9)

13 (48.1)

0.555

Days of Hospitalization before sending mcfDNA test, Median (Q1, Q3)

11.00 (5.00, 21.50)

9.50 (3.00, 18.25)

0.361